Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: A phase I/II study

Journal of Molecular Medicine

Volumn 77, Issue 4, 1999, Pages 393-398

  Löhr, Matthias ^a   Tibor Bago, Zoltan ^e   Bergmeister, Helga ^d   Ceijna, Manfred ^d   Freund, Mathias ^a   Gelbmann, Wolfgang ^e   Günzburg, Walter H ^e   Jesnowski, Ralf ^a   Hain, Johannes ^b   Hauenstein, Karlheinz ^a   Henninger, Wolfgang ^e   Hoffmeyer, Anne ^a,b   Karle, Peter ^e   Kröger, Jens Christian ^a   Kundt, Günther ^a   Liebe, Stefan ^a   Losert, Udo ^d   Müller, Petra ^a   Probst, Alexander ^e   Püschel, Katrin ^b   Renner, Matthias ^b,e   Renz, Renate ^b,e   Saller, Robert ^b   Salmons, Brian ^b   Schuh, Maximilian ^e   Schwendenwein, Ilse ^d   Von Rombs, Kerstin ^b   Wagner, Thomas ^c   Walter, Ingrid ^f   more..

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Bavarian Nordic GmbH   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^f Inst of Histology and Embryology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE; PENTOXYRESORUFIN DEALKYLASE;

ARTICLE; CANCER STAGING; CELL TRANSPLANTATION; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INDUCTION; FEMALE; GENE TARGETING; HUMAN; MALE; MICROENCAPSULATION; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; CELL LINE; CYTOCHROME P-450 CYP2B1; DRUG COMPOUNDING; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TRANSFECTION;

EID: 0003374533     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090050366     Document Type: Article

References (27)

1. Nowoursian MR, Burkert H, Herdrich K, Pohl J (1993) Ifosfamide in cancer therapy. A comparison with cyclophosphamide. Universitätsverlag, Jena
2. Gad-el-Mawla N (1986) Ifosfamide in advanced pancreatic cancer. Cancer Chemother Pharmacol 18 [Suppl 2]:55-56
3. Einhorn LH, Loehrer PJ (1986) Ifosfamide chemotherapy for pancreatic carcinoma. Cancer Chemother Pharmacol 18 [Suppl 2]:51-54
4. Genka S, Deutsch J, Stahle PL, Shetty UH, John V, Rapoport SI, Greig NH (1990) Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol 27:1-7
5. Dirven HAAM, van Ommen B, van Blaederen PJ (1996) Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 9:351-360
6. Stange J, Mitzner S, Dautzenberg H, et al (1993) Prolonged biochemical and morphological stability of encapsulated liver cells - a new method. Biomater Art Cells Immob Biotech 21:343-352
7. Parker SL, Tong T, Bolden S, Wingo PA (1996) Cancer statistics 1996. CA Cancer J Clin 46:5-27
8. Riela A, Zinsmeister AR, Melton LJ III, Weiland LH, DiMagno EP (1992) Increasing incidence of pancreatic cancer among women in Olmstedt County, Minnesota, 1940 through 1988. Mayo Clin Proc 67:839-845
9. Rosewicz S, Wiedenmann B (1997) Pancreatic carcinoma. Lancet 349:485-489
10. Evans DB, Staley CA, Lee JE, Pisters PWT, Abbruzzese JL (1996) Adenocarcinoma of the pancreas: recent controversies, current management, and future therapies. GI Cancer 1:149-161
11. Abrams RA, Grochow LB (1995) Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg Clin North Am 75:925-938
12. Ahlgren JD (1996) Chemotherapy for pancreatic carcinoma. Cancer 78:654-663
13. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG (1995) Regionale Chemotherapie beim fortgeschrittenen Pankreaskarzinom. Med Klin 90:501-505
14. Gansauge F, Link KH, Rilinger N, Kunz R, Beger HG (1996) Adjuvante regionale Chemotherapie beim resezierten fortgeschrittenen Pankreascarcinom. Chirurg 67:362-365
15. Benard J, Bourhis J, Riou G (1990) Clinical significance of multiple drug resistance in human cancers. Anticancer Res 10:1297-1302
16. Chabot GG (1994) Factors involved in clinical pharmacology variability in oncology. Anticancer Res 14:2269-2272
17. Carmichael J, Fink U, Russell RCG, et al (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73:101-105
18. Cerny T, Martinelli G, Goldhirsch A, et al (1991) Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study. J Cancer Res Clin Oncol 117 [Suppl IV]:S135-S138
19. Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJH, Cleton FJ (1995) Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol 121:297-302
20. Kedzie KM, Balfour CA, Escobar GY, et al (1991) Molecular basis for a functionally unique cytochrome P450IIB1 variant. J Biol Chem 266:22515-22521
21. Chen L, Waxman DJ, Chen D, Kufe DW (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 56:1331-1340
22. Löhr M, Müller P, Karle P, et al (1998) Targeted chemotherapy by encapsulating cells engineered to deliver CYP2B1, an ifosfamide activating cytochrome P450 gene. Gene Therapy 5:1070-1078
23. Donato MT, Gomez-Lechon MJ, Castell JV (1993) A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human rat hepatocytes cultured on 96-well plates. Anal Biochem 213:29-33
24. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42
25. Karle P, Müller P, Saller R, et al (1998) Intratumoral injection of encapsulated L 293 cells producing an ifosfamide activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 451:97-106
26. Ostrove JM (1994) Safety testing programs for gene therapy viral vectors. Cancer Gene Ther 1:125-131
27. Crandell RA, Fabricant CG, Nelson-Rees WA (1973) Development, characterization, and viral susceptibility of a feline (Felis catus) renal cell line (CRFK). In Vitro 9:176-185